Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coley Doubles Toll-Like Receptor Patent Estate With Purchase Of 3M Program

This article was originally published in The Pink Sheet Daily

Executive Summary

$20 million investment also gains the TLR-focused firm a pipeline of small molecule candidates targeting TLR7 and TLR8, as well as a 10,000 compound library.
Advertisement

Related Content

Pfizer Strengthens Therapeutic Vaccine Position With Coley Purchase
Pfizer Strengthens Therapeutic Vaccine Position With Coley Purchase
Pfizer Picks Second TRL9 Candidate From Coley For Development In Oncology
Pfizer Halts Lung Cancer Trials Of Toll-Like Receptor Agent
Array/VentiRx Partner On Toll-Like Receptor Drugs In Oncology, Allergy
Merck To Incorporate Idera’s TLR Agonists Into Vaccine Program
Newcomer Graceway Acquires 3M’s American Pharmaceutical Business
Newcomer Graceway Acquires 3M’s American Pharmaceutical Business
Dynavax Deal Could Bolster AstraZeneca’s Respiratory Disease Portfolio
Pfizer/Coley Prep Phase III Study Of ProMune For First-Line Lung Cancer

Topics

Advertisement
UsernamePublicRestriction

Register

PS066165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel